Circulating antigen-primed cytotoxic T-cells in patients with renal tumors treated with surgery.

[1]  Mojun Zhu,et al.  Understanding Suboptimal Response to Immune Checkpoint Inhibitors , 2022, Advanced biology.

[2]  R. Uzzo,et al.  The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Real-World Multi-Institutional Analysis , 2022, The Journal of urology.

[3]  Sean S. Park,et al.  Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer , 2021, Clinical Cancer Research.

[4]  C. Morrison,et al.  T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors , 2021, Nature Communications.

[5]  Le Xu,et al.  Intratumoral CXCL13+CD8+T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma , 2021, Journal for ImmunoTherapy of Cancer.

[6]  J. Cheville,et al.  Creation of a primary tumor tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma. , 2020, Urologic oncology.

[7]  R. McWilliams,et al.  Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients , 2020, Melanoma research.

[8]  B. Dai,et al.  Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients , 2020, Cancer Immunology, Immunotherapy.

[9]  Le Xu,et al.  Tumor-infiltrating TNFRSF9+ CD8+ T cells define different subsets of clear cell renal cell carcinoma with prognosis and immunotherapeutic response , 2020, Oncoimmunology.

[10]  G. Naik,et al.  Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma , 2019, Journal of Immunotherapy for Cancer.

[11]  Sean S. Park,et al.  Prospective Immunophenotyping of CD8+ T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT. , 2019, International journal of radiation oncology, biology, physics.

[12]  J. Cheville,et al.  The Probability of Aggressive Versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment. , 2018, European urology.

[13]  K. Bensalah,et al.  Sunitinib Alone or after Nephrectomy in Metastatic Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[14]  Sean S. Park,et al.  CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. , 2018, JCI insight.

[15]  A. Ravaud,et al.  Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study , 2018, Clinical Cancer Research.

[16]  G. Sica,et al.  Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients , 2017, Proceedings of the National Academy of Sciences.

[17]  C. Compton,et al.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging , 2017, CA: a cancer journal for clinicians.

[18]  P. Validire,et al.  Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma , 2017, Clinical Cancer Research.

[19]  R. Motzer,et al.  Systemic Therapy for Metastatic Renal-Cell Carcinoma. , 2017, The New England journal of medicine.

[20]  Sean S. Park,et al.  T cell Bim levels reflect responses to anti-PD-1 cancer therapy. , 2016, JCI insight.

[21]  J. Gartner,et al.  Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients , 2016, Nature Medicine.

[22]  S. Signoretti,et al.  Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial , 2014, Clinical Cancer Research.

[23]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[24]  L. Norian,et al.  Minimal changes in the systemic immune response after nephrectomy of localized renal masses. , 2014, Urologic oncology.

[25]  D. Douek,et al.  PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. , 2014, The Journal of clinical investigation.

[26]  S. Markovic,et al.  Endogenous tumor-reactive CD8+ T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth , 2013, Oncoimmunology.

[27]  Haidong Dong,et al.  B7-H1 limits the entry of effector CD8+ T cells to the memory pool by upregulating Bim , 2012, Oncoimmunology.

[28]  C. Drake,et al.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. , 2012, Current opinion in immunology.

[29]  N. Munshi,et al.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.